Hindustan Laboratories is trying to raise money through IPO with Sebi

Generic drug maker Hindustan Laboratories has filed preliminary documents with capital markets regulator Sebi to raise money through an initial public offering (IPO).The company’s maiden public offer involves a fresh issue of 50 lakh shares along with an offer for sale (OFS) of 91 lakh shares by the promoter, as per the draft red herring prospectus (DRHP).

The company proposes to use the proceeds from the IPO to finance working capital needs and general corporate purposes.

Hindustan Laboratories is an Indian pharmaceutical company primarily engaged in the large-scale manufacturing and supply of generic pharmaceuticals to government agencies under a business-to-government (B2G) framework.

The company supplied its products across India to 27 states and Union Territories during the six months ended September 30, 2025.

The product portfolio covers a broad range of therapeutic segments that address both acute and chronic healthcare needs. These include anti-allergic, anti-diabetic, anti-infectious, anti-malarial, anti-parasitic, blood-related, cardiac, gastrointestinal, keratolytic, nutritional and mineral supplements, pain and analgesics, respiratory, nutritional and mineral supplements and vitamin supplements.

Choice Capital Advisors has been appointed as book-running lead manager for the issue.